<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685538</url>
  </required_header>
  <id_info>
    <org_study_id>CHL.3/01-2019/M</org_study_id>
    <nct_id>NCT04685538</nct_id>
  </id_info>
  <brief_title>Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.</brief_title>
  <official_title>A Prospective, Observer-masked, Randomized Clinical Trial to Investigate and Compare the Clinical Efficacy of Chloroprocaine 3% Gel and Tetracaine 0.5% Eye Drop as Topical Anestheticsin Phacoemulsification.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sintetica SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sintetica SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial, multicenter, two-armed, to investigate and compare the clinical&#xD;
      efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anestheticsin&#xD;
      phacoemulsification. This prospective, observer masked, randomised, controlled, equivalence&#xD;
      phase 3 study will be conducted in approximately 4 European Countries. Sintetica intends to&#xD;
      perform a phase 3 study on patients undergoing cataract surgery to assess the safety and&#xD;
      efficacy of topical anaesthesia using chloroprocaine gel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective,randomized, multi-center, active-controlled, masked-observer, parallel-group,&#xD;
      competitive equivalence study. The study has been designed to assess the equivalence of&#xD;
      chloroprocaine 3% gel (Test) with respect to tetracaine 0.5% solution (Reference) in surface&#xD;
      anesthesia. Patients in both groups will receive three drops of study products before&#xD;
      surgery. The study will include a Selection visit (Day -90/Day -1), an Inclusion visit (Day&#xD;
      1/surgery day), a Follow-up visit (Day 2, phone visit), a Final visit (Day 8), and a&#xD;
      Follow-up phone call - Optional (Day 28, phone visit).&#xD;
&#xD;
      Selection visit (Visit 1, Day -90/Day -1):&#xD;
&#xD;
      Patients scheduled to undergo cataract surgery in a single eye will be informed about the&#xD;
      aims, procedures and possible risks of the study and will be asked to sign the informed&#xD;
      consent form for the inclusion in the trial.&#xD;
&#xD;
      Inclusion visit/Surgery (Visit 2, Day 1):&#xD;
&#xD;
      Before the anesthesia, patients will be questioned about previous and concomitant ocular and&#xD;
      non-ocular treatments. Inclusion /exclusion criteria and patient status will be verified.&#xD;
      Patients will be randomized to either chloroprocaine 3% gel (Test) or tetracaine 0.5% eye&#xD;
      drop (Reference) treatment group.&#xD;
&#xD;
      Follow-up visit/phone visit (Visit 3, Day 2):&#xD;
&#xD;
      Concomitant ocular and non-ocular treatments, AEs, and patient global satisfaction will be&#xD;
      assessed.&#xD;
&#xD;
      Final visit (Visit 4, Day 8 ± 1 day):&#xD;
&#xD;
      Concomitant ocular and non-ocular treatments, ocular symptoms, best far corrected visual&#xD;
      acuity in both eyes, endothelial cell count, corneal thickness, blood pressure and heart&#xD;
      rate, and AEs will be assessed. Slit lamp examination and fluorescein test, IOP in both eyes,&#xD;
      and fundoscopy will be performed.&#xD;
&#xD;
      Optional visit/phone visit (Visit 5, Day 28 ± 3 days):&#xD;
&#xD;
      Concomitant ocular and non-ocular treatments and AEs resolution will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Actual">March 9, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects in each treatment group with a successful surface anesthesia.</measure>
    <time_frame>Before IOL implantation surgery.</time_frame>
    <description>Τhe primary endpoint is the proportion of subjects in each treatment group with a successful surface anesthesia, without any supplementation at the time point T4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular symptoms;</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Ocular symptoms (pain, irritation/burning/stinging, photophobia, foreign body sensation) will be graded by the patients according to the following scale: 0 = absent, 1&#xD;
= mild, 2 = moderate, 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective ocular signs</measure>
    <time_frame>up to 102 days</time_frame>
    <description>- Objective ocular signs (palpebral edema, chemosis, conjunctival hyperemia, conjunctival discharge, follico-papillary conjunctivitis, corneal staining punctuations, anterior chamber cells) assessed by slit lamp examination, flare, and other objective ocular signs will be graded according to the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit lamp examination</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Modification of the basal status of the assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell counts</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Modification of the basal status of the assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Modification of the basal status of the assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best far corrected visual acuity</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Modification of the basal status of the assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundoscopy</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Modification of the basal status of the assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>up to 102 days</time_frame>
    <description>Modification of the basal status of the assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs occurrence</measure>
    <time_frame>up to 133 days</time_frame>
    <description>Number of AE occuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon satisfaction</measure>
    <time_frame>day 1</time_frame>
    <description>Evaluation of surgeon satisfaction. How do you consider the study product global tolerance?:&#xD;
(0) = Very satisfactory&#xD;
= Satisfactory&#xD;
= Unsatisfactory&#xD;
= Very unsatisfactory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global satisfaction</measure>
    <time_frame>day 1</time_frame>
    <description>Patient global satisfaction at D1 based on a 5-question questionnaire read by a masked observer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Chloroprocaine 3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracaine 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroprocaine 3%</intervention_name>
    <description>Administration: three IMP drops instillation as follow:&#xD;
1st Drop instillation, then wait for 5 minutes&#xD;
Eye Disinfection, then wait for 2 minutes&#xD;
2nd Drop instillation, then wait for 1 minute&#xD;
3rdDrop instillation, then wait for 1 minute&#xD;
Start of Surgery.</description>
    <arm_group_label>Chloroprocaine 3%</arm_group_label>
    <other_name>Arm 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine 0.5%</intervention_name>
    <description>Administration: three IMP drops instillation as follow:&#xD;
1st Drop instillation, then wait for 5 minutes&#xD;
Eye Disinfection, then wait for 2 minutes&#xD;
2nd Drop instillation, then wait for 1 minute&#xD;
3rdDrop instillation, then wait for 1 minute&#xD;
Start of Surgery.</description>
    <arm_group_label>Tetracaine 0.5%</arm_group_label>
    <other_name>Arm 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent&#xD;
&#xD;
          2. Male or female aged≥ 18 years&#xD;
&#xD;
          3. Senile or pre-senile cataract&#xD;
&#xD;
          4. Scheduled to undergo cataract surgery in a single eyeat a time (clear corneal&#xD;
             self-sealing incisions - phacoemulsification - foldable intra-ocular lens surgery with&#xD;
             injector)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Combined surgery&#xD;
&#xD;
          2. Previous intraocular surgery&#xD;
&#xD;
          3. Previous corneal refractive surgeries less than 6 months before screening&#xD;
&#xD;
          4. Non Senile or non pre-senilecataract (e.g.: traumatic, pathological or congenital&#xD;
             cataract)&#xD;
&#xD;
          5. Pupillary abnormalities (irregular, etc.)&#xD;
&#xD;
          6. Iris synechiae&#xD;
&#xD;
          7. Eye movement disorder (nystagmus, etc.)&#xD;
&#xD;
          8. Dacryocystitis and all other pathologies of tears drainage system&#xD;
&#xD;
          9. History of Inflammatory ocular disease (Iritis, uveitis, herpetic keratitis)&#xD;
&#xD;
         10. Corneal, epithelial, stromal or endothelial, residual or evolutionary disease&#xD;
             (including corneal ulceration and superficial punctuate keratitis)&#xD;
&#xD;
         11. History of ocular traumatism, infection or inflammation within the last 3 months&#xD;
&#xD;
         12. Pseudo-exfoliation, exfoliative syndrome&#xD;
&#xD;
         13. Prior intravitreal injections within 7 days of the surgery&#xD;
&#xD;
         14. IOP over 25mmHg under treatment&#xD;
&#xD;
         15. Best corrected visual acuity &lt; 1/10&#xD;
&#xD;
         16. Patient already included in the study for phakoexeresis&#xD;
&#xD;
         17. History of ophthalmic surgical complication (cystoid macular oedema, etc.)&#xD;
&#xD;
         18. Diabetes mellitus&#xD;
&#xD;
         19. Surdity&#xD;
&#xD;
         20. Pakinsondisease&#xD;
&#xD;
         21. Excessive anxiety&#xD;
&#xD;
         22. Any other medical or surgical history, disorder or disease such as acute or chronic&#xD;
             severe organic disease: hepatic, endocrine neoplasic, hematological diseases, severe&#xD;
             psychiatric illness, relevant cardiovascular abnormalities (such as unstable angina,&#xD;
             bradycardia, atrial fibrillation,uncontrolled hypertension: systolic blood pressure&#xD;
             over 140 mm Hg, diastolic blood pressure over 90 mmHg) and/or any complicating factor&#xD;
             or structural abnormality judged by the investigator to be incompatible with the&#xD;
             study.&#xD;
&#xD;
         23. Known hypersensitivity to sulfonamides products or any of the components of the study&#xD;
             medications or to test products Specific exclusion criteria for women&#xD;
&#xD;
         24. Pregnancy (positive pregnancy test), lactation&#xD;
&#xD;
         25. Women of childbearing potential without an acceptable effective method of&#xD;
             contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive&#xD;
             implant) until end of the study participation OR&#xD;
&#xD;
         26. Women not hysterectomized, not menopaused nor surgically sterilized. Exclusion&#xD;
             criteria related to general conditions&#xD;
&#xD;
         27. Inability of patient and/or relatives to understand the study procedures and thus&#xD;
             inability to give informed consent&#xD;
&#xD;
         28. Non-compliant patient and/or relatives (e.g. not willing to attend the follow-up&#xD;
             visits, way of life interfering with compliance)&#xD;
&#xD;
         29. Participation in anotherclinicalstudy&#xD;
&#xD;
         30. Already included once in this study&#xD;
&#xD;
         31. Ward of court&#xD;
&#xD;
         32. Patient not covered by the Social Security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Alio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vissum Alicante, Calle del Cabañal 1, 03016 Alicante, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi - Dipartimento testa collo, U.O. Oftalmologia Ciardella</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Mater Domini di Catanzaro - U.O. Oculistica</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi di Firenze - Dipartimento neuromuscoloscheletrico e organi di senso, reparto di oculistica</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano&quot; - Dipartimento di chirurgia, U.O. Oculistica</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gruppo Multimedica Ospedale San Giuseppe di Milano - Clinica oculistica</name>
      <address>
        <city>Milano</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele IRCCS - Clinica oculistica</name>
      <address>
        <city>Milano</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Presidio Ospedale San Paolo - Dipartimento testa collo, reparto di oculistica</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo - Dipartimento di scienze chirurgiche, U.O. Oculistica</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Perugia - Ospedale S. Maria della Misericordia di Perugia - Clinica oculistica</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana - Cisanello - D.A.I. Specialità chirurgiche, U.O. Oculistica</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-medico di Roma - U.O.C. Oftalmologia</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata - Dipartimento benessere della salute mentale e neurologica, dentale e degli organi di senso, U.O.S.D. Oculistica</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oftalmico di Roma (ASL Roma 1) - Dipartimento di oculistica e rete oftalmologica</name>
      <address>
        <city>Roma</city>
        <zip>00136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione G.B. Bietti di Roma - U.O.S. Segmento anteriore con annessi oculari</name>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Senese - Università degli Studi di Siena - Dipartimento della salute mentale e degli organi di senso, U.O.C. Oculistica</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Sanitaria Universitaria Integrata di Udine - P.O. Universitario &quot;Santa Maria della Misericordia&quot; - Dipartimento di chirurgia specialistica, clinica oculistica</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izak Vision Center s.r.o.</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP F. D. Roosevelta Banská Bystrica II. Očná klinika SZU</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ROBIN LOOK spol. s r.o., Centrum mikrochirurgie oka</name>
      <address>
        <city>Bratislava</city>
        <zip>821 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vesely Očná Klinika, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>821 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3F s.r.o. Očná ambulancia a optika</name>
      <address>
        <city>Košice</city>
        <zip>040 11</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVEA KLINIKA, s.r.o.</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIDISSIMO s. r. o. Očná klinika</name>
      <address>
        <city>Trenčín</city>
        <zip>911 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou Žilina Očné oddelenie</name>
      <address>
        <city>Žilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oftalvist Cio Jerez Clinic</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cadiz</state>
        <zip>11408</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vissum alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Integral Servicio de Oftalmología Admiravisión en Clínica Corachan</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Eye</keyword>
  <keyword>Chloroprocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 19, 2021</submitted>
    <returned>November 17, 2021</returned>
    <submitted>November 18, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

